The article below may contain offensive and/or incorrect content.
Disabling the CD161 pathway restores the T-cell's ability to attack gliomas and extends lifespan in animal models of brain cancer.Article Correctness Is Author's Responsibility: New Immunotherapy Target Discovered for Malignant Brain Tumors
Disabling the CD161 pathway restores the T-cell's ability to attack gliomas and extends lifespan in animal models of brain cancer.
